Relay Therapeutics, Inc. (RLAY)
Automate Your Wheel Strategy on RLAY
With Tiblio's Option Bot, you can configure your own wheel strategy including RLAY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RLAY
- Rev/Share 0.0454
- Book/Share 4.2609
- PB 0.7229
- Debt/Equity 0.0654
- CurrentRatio 19.9627
- ROIC -0.4925
- MktCap 528050600.0
- FreeCF/Share -1.6109
- PFCF -1.937
- PE -1.5635
- Debt/Assets 0.059
- DivYield 0
- ROE -0.4416
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | RLAY | Wells Fargo | -- | Equal Weight | -- | $4 | April 17, 2025 |
| Resumed | RLAY | Goldman | -- | Buy | -- | $20 | Sept. 10, 2024 |
| Upgrade | RLAY | Jefferies | Hold | Buy | $10.6 | $16 | Sept. 10, 2024 |
| Downgrade | RLAY | Oppenheimer | Outperform | Perform | -- | -- | Sept. 10, 2024 |
News
What Makes Relay Therapeutics (RLAY) a New Buy Stock
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.
Read More
Relay Therapeutics: A Precision Oncology Play Worth The Risk
Published: February 14, 2025 by: Seeking Alpha
Sentiment: Positive
Relay Therapeutics focuses on selective small-molecule inhibitors, with RLY-2608 showing promise in breast cancer and a solid cash position lasting into 2027. Financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns about expense control and sustainable cash flow. Out-licensing RLY-4008 to Elevar Therapeutics secures up to $500 million in milestones, allowing RLAY to concentrate on RLY-2608's clinical trials.
Read More
About Relay Therapeutics, Inc. (RLAY)
- IPO Date 2020-07-16
- Website https://www.relaytx.com
- Industry Biotechnology
- CEO Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
- Employees 259